RxDoctor Payments Data

Dunni Adalumo, MD

Family Medicine · Tracy, CANPI 1447578331

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 74 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$210
  • AstraZeneca$188
  • Edwards Lifesciences$139
  • Amgen$128
  • Novo Nordisk$110
  • Johnson & Johnson$86
  • plus $464 from 11 others

What the payments were for

  • Food & beverage$1,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$77,307
Medicare patients
196
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$62,110
JardianceEmpagliflozin26$29,959
RybelsusSemaglutide17$22,425
JanuviaSitagliptin Phosphate11$17,184
Breo ElliptaFluticasone/Vilanterol18$11,999
TradjentaLinagliptin14$9,597
Tresiba Flextouch U-100Insulin Degludec16$8,158
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,469
Atorvastatin Calcium237$1,926
Albuterol Sulfate HfaAlbuterol Sulfate45$1,472
Levothyroxine Sodium93$1,268
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$1,218
Losartan Potassium117$1,184
Gabapentin63$1,083
Amlodipine Besylate176$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$110$84,53547 claims
Boehringer IngelheimJardiance, Tradjenta$210$39,55640 claims
MerckJanuvia$23$17,18411 claims
GSKBreo Ellipta$78$11,99918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →